Boundless Bio Inc
BOLD1.200USD
+0.040+3.45%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
26.76MCap. mercado
PérdidaP/E TTM
Más Datos de Boundless Bio Inc Compañía
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
Información de la empresa
Símbolo de cotizaciónBOLD
Nombre de la empresaBoundless Bio Inc
Fecha de salida a bolsaMar 28, 2024
Director ejecutivoMr. Zachary D. Hornby
Número de empleados64
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 28
Dirección10955 Alexandria Way
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Teléfono18587669912
Sitio Webhttps://boundlessbio.com/
Símbolo de cotizaciónBOLD
Fecha de salida a bolsaMar 28, 2024
Director ejecutivoMr. Zachary D. Hornby
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Dr. James G. (Jamie) Christensen, Ph.D.
Dr. James G. (Jamie) Christensen, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Doebele
Mr. Robert (Bob) Doebele
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jakob Loven, Ph.D.
Dr. Jakob Loven, Ph.D.
Director
Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 14 de may
Actualizado: mié., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
27.63%
Venture Capital
21.89%
Investment Advisor/Hedge Fund
11.86%
Hedge Fund
8.31%
Corporation
7.22%
Individual Investor
4.18%
Research Firm
0.51%
Pension Fund
0.10%
Bank and Trust
0.08%
Other
18.22%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
128
18.31M
81.78%
-1.81M
2025Q1
129
19.49M
87.25%
+660.31K
2024Q4
119
19.41M
87.06%
+540.27K
2024Q3
106
19.47M
87.42%
+538.85K
2024Q2
87
20.07M
90.11%
+1.04M
2024Q1
53
20.35M
91.48%
+20.35M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
3.15M
14.08%
-187.23K
-5.61%
Mar 31, 2025
ARCH Venture Partners
2.69M
12.03%
--
--
Apr 25, 2025
RA Capital Management, LP
2.18M
9.74%
--
--
Mar 31, 2025
Bayer HealthCare LLC
1.62M
7.22%
--
--
Apr 25, 2025
Nextech Invest, Ltd.
1.23M
5.49%
--
--
Mar 31, 2025
Citadel Advisors LLC
830.94K
3.71%
+40.30K
+5.10%
Mar 31, 2025
Redmile Group, LLC
725.20K
3.24%
-15.00K
-2.03%
Mar 31, 2025
Sectoral Asset Management Inc.
678.57K
3.03%
--
--
Mar 31, 2025
Lim (Jonathan E)
653.48K
2.92%
--
--
Apr 25, 2025
BlackRock Institutional Trust Company, N.A.
587.40K
2.62%
-9.12K
-1.53%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
